Biontech And Pfizer are Getting Closer to Emergency Approval in USA

According to a new assessment by the US Medicines Agency, emergency approval for Biontech and Pfizer‘s corona vaccine in the United States is getting closer. Competitor Astrazeneca, on the other hand, receives a new damper.

The Mainz-based company Biontech and its US partner Pfizer submitted an application to the FDA for emergency approval of their vaccine on November 20. The FDA advisory committee meets on Thursday to decide on an emergency approval. The statement now suggests that the regulator tends to give the green light to Biontech and Pfizer’s vaccine.

The most common side effects identified were injection site reactions, fatigue and headache, followed by muscle pain, chills, joint pain and fever. There were more severe reactions only in up to 4.6 percent of the participants. They occurred more frequently in subjects aged 12 and over (4.6 percent) than in the group of people over 55 (2.8 percent). The experts suspected that this was due to the younger people’s better immune defenses.

Unwanted, particularly severe side effects that would have to be treated in hospital, for example, were found in less than 0.5 percent of the test persons – and these were just as common in the group that received only a placebo as in the group that was actually vaccinated. That would indicate that they were not caused by the vaccine.

Astrazeneca and Oxford University vaccine needs further investigation
In addition, the FDA confirmed information from Pfizer and Biontech that their vaccine is 95 percent effective. It works for people of all ages, genders and ethnicities as well as for risk groups with previous illnesses.

Reviewer overview

Biontech and Pfizer are Getting Closer to Emergency Approval in USA - /10

Summary

0 Bad!